Thymopentin in the treatment of severe alopecia areata

A. Tosti, P. Manuzzi, A. Gasponi

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


Since alopecia areata might be due to an aberrant T-cell-mediated immunity, the purpose of our study was to compare the results obtained with Thymopentin to those of topical sensitizing therapies, such as squaric acid dibutylester or diphencyprone. Statistical analysis showed no differences between the results obtained with these two therapies. Therefore, Thymopentin can be considered to be a new therapeutic agent which, like the classic topical drugs squaric acid dibutylester or diphencyprone, has immunoreactive properties and might provide some hope to patients with severe alopecia areata.

Original languageEnglish (US)
Pages (from-to)170-174
Number of pages5
Issue number3
StatePublished - 1988
Externally publishedYes

ASJC Scopus subject areas

  • Dermatology


Dive into the research topics of 'Thymopentin in the treatment of severe alopecia areata'. Together they form a unique fingerprint.

Cite this